Prosecution Insights
Last updated: April 18, 2026
Application No. 18/687,697

Method for producing mixtures containing 2-(2-hydroxyethyl)-piperidinyl carbamide acid secondary butyl ester

Non-Final OA §102
Filed
Feb 28, 2024
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Saltigo GmbH
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-14 are pending. Claims 3-14 are withdrawn. Claims 1-2 are rejected. Priority This is a 35 U.S.C. 371 National Stage Filing of International Application No. PNG media_image1.png 24 202 media_image1.png Greyscale , which claims priority under 35 U.S.C. 119(a-d) to PNG media_image2.png 23 173 media_image2.png Greyscale . Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d). Information Disclosure Statement The Information Disclosure Statement (IDS’s) submitted on 2/29/2024 and 4/10/2025 were considered by the Examiner. Election/Restrictions Applicant's election with traverse of Group I (claims 1 and 2) in the reply filed on 2/4/2026 is acknowledged. The traversal is on the ground(s) that the art used in the restriction requirement of 12/5/2025 was not applicable. The prosecution of this application was transferred to Examiner Meghan Heasley on 3/15/2026. This is not found persuasive because there is applicable art to break unity, which is described in the 102 rejection below (US5304650). The requirement is still deemed proper and is therefore made FINAL. Claims 3-14 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 2/4/2026. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1 and 2 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Krebs et al. (US5304650-disclosed on Applicant 2/29/2024 IDS). Regarding instant claim 1, which is drawn to a mixture which may be 100% of formula (I): PNG media_image3.png 233 359 media_image3.png Greyscale , Krebs discloses an identical compound on the top of column 3: PNG media_image4.png 128 152 media_image4.png Greyscale . A mixture which is 100% by weight of a compound is simply just that compound. Additionally, regarding the instant limitation of “wherein the mixture has a Hazen color number of 0 to 15…” this would be inherent in a prior art reference of identical composition. The limitation of instant claim 2 is not required because it depends from instant claim 1, wherein the mixture may be 100% of instant formula (I). Therefore, any additional components under these circumstances are not required limitations. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 28, 2024
Application Filed
Apr 06, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month